Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/NKB2 stock hub

FRA/NKB2 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/NKB2is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

5.2B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/NKB2

In the news

Latest news · FRA/NKB2

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E20

P25 n/aP50 n/aP75 n/a

Trailing P/E12.9

P25 n/aP50 n/aP75 n/a

ROE112.6

P25 n/aP50 n/aP75 n/a

ROIC18.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/NKB2 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	399
Employees Change	55%
Employees Change Percent	17.24
Enterprise value	EUR 5.4B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 5.2B
Price	EUR 35.9
Price currency	EUR
Rev Per Employee	1,522,337.56x
Sic	2834
Symbol	fra/NKB2
Website	https://www.tgtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.76%
EV Earnings	13.39x
EV/EBIT	42.23x
EV/EBITDA	41.67x
EV/FCF	-435.81x
EV/Sales	9.01x
FCF yield	-0.24%
Forward P/E	20.02x
P/B ratio	10.2x
P/E ratio	12.88x
P/S ratio	8.5x
PE Ratio3 Y	80.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	21.35%
EBITDA Margin	21.36%
Gross margin	83.05%
Gross Profit	EUR 504.5M
Gross Profit Growth	72.19%
Gross Profit Growth Q	62.76%
Gross Profit Growth3 Y	322.97%
Gross Profit Growth5 Y	276.58%
Net Income	EUR 400.6M
Net Income Growth	1,079.81%
Net Income Growth Q	290.85%
Pretax Margin	17.46%
Profit Margin	65.95%
Profit Per Employee	EUR 1M
ROA	8.55
Roa5y	-14.08
ROCE	11.14
ROE	112.6
Roe5y	-23.37
ROIC	18.89

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	17.77%
Cagr1y	18.03%
Cagr3y	4.25%
Cagr5y	1.71%
EPS Growth	1,105.5
EPS Growth Q	300
Revenue Growth	81.26x
Revenue Growth Q	69.56x
Revenue Growth3 Y	333.92x
Revenue Growth5 Y	278.04x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.64
Assets	EUR 1.3B
Cash	EUR 446.2M
Current Assets	EUR 921.7M
Current Liabilities	EUR 158.7M
Debt	EUR 653.6M
Debt EBITDA	EUR 4.97
Debt Equity	EUR 1.29
Debt FCF	EUR -53.1
Equity	EUR 505.7M
Interest Coverage	5.41
Liabilities	EUR 820.2M
Long Term Assets	EUR 404.3M
Long Term Liabilities	EUR 661.6M
Net Cash	EUR -207.4M
Net Cash By Market Cap	EUR -4.02
Net Debt EBITDA	EUR 1.6
Net Debt Equity	EUR 0.41
Tangible Book Value	EUR 505.7M
Tangible Book Value Per Share	EUR 3.57

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.81
Inventory Turnover	0.83
Net Working Capital	EUR 335.9M
Quick ratio	4.84
Working Capital	EUR 780.4M
Working Capital Turnover	EUR 0.88

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	413.22%
1Y total return	18.01%
200-day SMA	27.06
3Y total return	13.29%
50-day SMA	27.79
50-day SMA vs 200-day SMA	50over200
5Y total return	8.82%
All Time High	52.04
All Time High Change	-31.01%
All Time High Date	2021-02-08
All Time Low	2.3
All Time Low Change	1,463.59%
All Time Low Date	2013-11-19
ATR	0.95
Ch YTD	40.29
High	35.9
High52	35.9
High52 Date	2026-05-08
High52ch	0%
Low	35.9
Low52	22.47
Low52 Date	2025-08-12
Low52ch	59.8%
Ma50ch	29.2%
Price vs 200-day SMA	32.68%
RSI	74.96
RSI Monthly	62.11
RSI Weekly	69.6
Sharpe ratio	0.53x
Sortino ratio	0.97
Total Return	2.27%
Tr YTD	40.29
Tr1m	24.22%
Tr1w	25.52%
Tr3m	54.48%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 129.7M
Operating Income Growth	149.9
Operating Income Growth Q	303.6
Operating margin	21.35

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	135,104,730%
Net Borrowing	417,753,567.1
Shares Insiders	4.63%
Shares Institutions	77.2%
Shares Qo Q	0.44%
Shares Yo Y	-2.27%
Short Ratio	14.07

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -72.7M
Average Volume	157.2x
Bv Per Share	3.57
CAPEX	EUR -208,152
Ch10y	413.2
Ch1m	24.22
Ch1w	25.52
Ch1y	18.01
Ch3m	54.48
Ch3y	13.29
Ch5y	8.82
Ch6m	25.88
Change	1.41%
Change From Open	0
Close	35.4
Days Gap	1.41
Depreciation Amortization	70,380.8
Earnings Date	2026-05-06
EBIT	EUR 129.7M
EBITDA	EUR 129.7M
EPS	EUR 2.49
F Score	3
FCF	EUR -12.3M
FCF EV Yield	-0.23x
Financing CF	266,436,295
Fiscal Year End	December
Founded	1,993
Graham Number	14.85262
Graham Upside	-58.63
Income Tax	EUR -294.5M
Investing CF	14,630,484
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Ma150	27.2
Ma150ch	32.01%
Ma20	30.39
Ma20ch	18.13%
Net CF	268,967,076
Open	35.9
Ppne	5,495,641.7
Price Date	2026-05-08
Price EBITDA	EUR 39.78
Ptbv Ratio	10.2
Relative Volume	0.75x
Revenue	607,412,688x
SBC By Revenue	9.94x
Share Based Comp	60,405,710
Tax By Revenue	-48.49x
Tr6m	25.88%
Z Score	3.61

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/NKB2 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/NKB2 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/NKB2?

Insider, institutional, and short-interest positioning.

Institutional ownership

+77.2%

Share of float held by funds and institutions

Insider ownership

+4.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/NKB2 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

75.0

Above 70: short-term overbought

Price vs 200-day MA

+32.7%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.53

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/NKB2

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/NKB2 stock rating?

fra/NKB2 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/NKB2 analysis?

The full report lives at /stocks/fra/NKB2/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/NKB2?

The latest report frames fra/NKB2 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/NKB2 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.